Paying dearly

October 4, 2004

Dr. Centor links to a NY Times article asking whether the Vioxx findings are a class effect. He also ends condemning direct-to-consumer advertising:

I would hold Vioxx up as a clear example of the dangers of DCA. DCA tries to spur demand. It did. And now Merck will probably pay. And maybe some patients have paid dearly.



Related posts:

  1. Vytorin, one of the worst blunders of the year?
  2. Will paying patients to lose weight be effective?
  3. My take: Paying for call, Muslims in medicine
  4. Medical device ads
  5. Avandia: A "flood" of lawsuits is coming
  6. Will Sanjay Gupta stand up to the lobbyists as Surgeon General?
  7. A jury of "uneducated casino workers" beat the hell out of Merck


KevinMD.com on Facebook


  Follow on Twitter   Subscribe



Tagged as: patient

Comments on this entry are closed.

Previous post: Contrast . . .

Next post: Why colon cleansing and colonic irrigation doesn’t work and can be harmful to patients

Site Meter